ResMed Inc: A Significant Upside Despite The Perceived Risk (NYSE:RMD)
· seekingalpha.com
ResMed (RMD) stock: why it de-rated despite 17% EPS growth. Mask/consumables revenue and key risks analyzed, with $280–$300 target.
ResMed ( RMD ) closed at $290.65 on 22 August 2025. Today the stock trades around $232 even though non-GAAP earnings per share increased 17% to $11.17 over the ...